WO1996016332A1 - Recuperation d'agents de liaison specifiques et utilisations de ceux-ci - Google Patents

Recuperation d'agents de liaison specifiques et utilisations de ceux-ci Download PDF

Info

Publication number
WO1996016332A1
WO1996016332A1 PCT/EP1995/004518 EP9504518W WO9616332A1 WO 1996016332 A1 WO1996016332 A1 WO 1996016332A1 EP 9504518 W EP9504518 W EP 9504518W WO 9616332 A1 WO9616332 A1 WO 9616332A1
Authority
WO
WIPO (PCT)
Prior art keywords
analogue
specific binding
target ligand
binding agent
affinity
Prior art date
Application number
PCT/EP1995/004518
Other languages
English (en)
Inventor
Robert Andrew Badley
Mark John Berry
Philip Porter
Trevor Anthony Kenneth Wattam
Original Assignee
Unipath Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unipath Limited filed Critical Unipath Limited
Priority to AU41176/96A priority Critical patent/AU4117696A/en
Priority to EP95939289A priority patent/EP0793806B1/fr
Priority to AT95939289T priority patent/ATE237137T1/de
Priority to DE69530315T priority patent/DE69530315T2/de
Publication of WO1996016332A1 publication Critical patent/WO1996016332A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/106664—Blood serum or blood plasma standard or control

Definitions

  • This invention relates to processes for the recovery of and uses of specific binding agents.
  • Affinity purification in which the desired specific binding agent is selectively adsorbed onto .a solid phase material and subsequently eluted, is an alternative.
  • a highly efficient way of extracting the desired specific binding agent from the cell culture medium is to expose the medium to a solid phase, such as a column, onto which is immobilised the target ligand against which the specific binding agent has been raised.
  • the present invention provides a much improved method for recovering high affinity specific binding agents in active form.
  • the invention uses the known principle of selective adsorption of the specific binding agent onto a solid phase bearing an immobilised analogue of the target ligand.
  • subsequent retrieval of the specific binding agent is achieved by exposing the solid phase to a medium containing a second analogue of the target ligand, the affinity of the specific binding agent for the second analogue being of intermediate magnitude. Due to the reversible nature of specific binding reactions, when the solid phase onto which the high affinity specific binding agent has been adsorbed is in the presence of the medium-affinity second analogue, the specific binding agent is progressively released from the solid phase into the medium and binds preferentially to -the second analogue.
  • the complex formed between the specific binding agent and the second analogue will itself dissociate readily in the presence of the target ligand and the target ligand will bind preferentially to the specific binding agent.
  • the complex formed between the specific binding agent and the second analogue can be used for example in assays intended to detect the target ligand, in the same manner as a conventional uncomplexed specific binding agent.
  • the displacement of the second analogue can be used as part of the assay result detection system, for example by having a detectable label attached to the second analogue.
  • a further and highly important benefit associated with the invention is that we have found that the complex formed between the specific binding agent and the second analogue greatly assists in maintaining the functional stability of the specific binding agent. The reasons for this are not fully understood, but possibly this enhanced stability arises because the analogue is occupying the active binding site of the specific binding agent and protects this critical site against damage.
  • the invention therefore provides a very efficient way of recovering high affinity specific binding agents and of stabilising such agents prior to use.
  • the invention provides a process for recovering a specific binding agent possessing high affinity for a target ligand, in which process: a) a first medium containing the specific binding agent is contacted with a solid phase bearing immobilised thereon a first analogue for the target ligand, said specific binding agent possessing comparatively low affinity for said first analogue; b) following separation of the solid phase from said first medium, said solid phase is contacted with a second medium containing a second analogue for the target ligand, said specific binding agent possessing an intermediate affinity for said second analogue, whereby specific binding agent which has become bound to said solid phase is preferentially bound to said second analogue and thereby released from said solid phase in the form of a complex with said second analogue, but from which complex said second analogue can be displaced by exposure to said target ligand in bindable form.
  • the affinity of said specific binding reagent for said target ligand is at least about 5 times, more preferably at least about 20 times, and most preferably at least about 100 times greater than its affinity for said first analogue.
  • the affinity of said specific binding reagent for said target ligand is at least about 5, and more preferably at least about 10 times greater than its affinity for said second analogue.
  • binding agents to which the invention can be applied are antibodies or antibody fragments, such as Fab 2 , Fab or FV fragments.
  • Said second analogue can be an epitope mimic, i.e. a small molecule, generally of synthetic origin, such as a short peptide, which behaves in a manner comparable to the binding site (epitope) of the target ligand.
  • the invention can be applied advantageously when said target ligand is estradiol or a metabolite thereof, such as estrone-3-glucuronide (E3G).
  • said first analogue can be estrone.
  • said second analogue is estriol glucuronide.
  • estradiol-3-glucuronide can be used as the second analogue; in this case, estriol-3-glucuronide may optionally be used as the first analogue.
  • the invention also provides a reagent comprising a specific binding agent for a target ligand, said specific binding agent being complexed with an analogue of said target ligand, the affinity of said specific binding agent for said analogue being substantially less than its affinity for said target ligand such that, when said complex is exposed to said target ligand in bindable form (i.e. the relevant epitope of the target ligand is free to engage in complex formation with the specific binding agent), said target ligand displaces said analogue from said complex and preferentially binds to said specific binding agent.
  • Examples 1 to 7 describe the recovery and analysis of a monoclonal antibody (and its corresponding Fv fragment) raised against the steroid hormone estrone-3-glucuronide.
  • the chemical structure of estrone-3-glucuronide, and the analogues used in these Examples, are shown in Figure 1. Also shown is the extent to which the analogues cross-react with the monoclonal antibody. Details of how to generate cross-reactivity data are given in Gani et al (1994).
  • Figure 1 depicts structural formulae of four metabolites used in the following examples, namely:
  • Estrone beta-D-glucuronide also known as 1,3,5[10]-Estratrien-3-ol-17-one 3- glucuronide; or 3-Hydroxy-1,3,5[10]-estratrien-17-one 3-glucronide.
  • 17beta-Estradiol 3-(beta-D-glucuronide) also known as 1,3,5[10]-Estratrien-3,17beta-diol 3-glucuronide; or 3,17beta-Dihydroxy-1,3,5[10]-estratriene 3- glucuronide. 20% Cross Reactive with I.
  • Estriol 3-(beta-D-glucuronide) also known as 1,3,5[10]-Estratrien-3,16alpha,17beta-triol 3- glucuronide; or 3, 16alpha,17beta-Trihydroxy-1,3,5[10]- estratriene 3-glucuronide. 0.7% Cross Reactive with I.
  • Estrone also known as 1,3,5[10]-Estratrien-3-ol-17- one; or 3-Hydroxy-1,3,5[10]-estratrien-17-one. 0.1% Cross Reactive with I.
  • Figure 2 compares the specific activities, expressed as absorbance at 450nm, of various antibody fractions (see Example 4).
  • Figure 3 compares the retention of specific activity, again expressed as absorbance at 450 nm, during storage of an antibody prepared in accordance with the invention and one prepared by conventional means (see Example 7).
  • estrone was coupled to a chromatography medium which had been derivatised with epoxy groups (Pharmacia epoxy 6B Sepharose) according to the protocol below:- i) 3g of epoxy 6B Sepharose [Pharmacia] was weighed out into a 200ml glass beaker. 200mls of MilliQ water was added, and the gel was left to resuspend for 30 minutes. ii) 4.3mg of estrone [Sigma] was weighed out into a sterile glass universal. This was dissolved in 5mls of HPLC grade dimethylformamide (DMF) [Aldrich].
  • DMF dimethylformamide
  • the glass universal was then placed in a 45°C incubator with slow rotation for at least 16 hours.
  • the Sepharose was again collected with a P16 sinta glass and washed with 200ml of 85% DMF in MilliQ, followed by 400mls of PBS.
  • the Sepharose was packed in a C16 column [Pharmacia] and stored at 4°C until required.
  • MAB monoclonal antibody
  • Hybridoma cells producing a monoclonal antibody (MAB) specific for estrone-glucuronide were grown up in culture medium according to standard techniques. This feedstock was clarified by centrifugation and then applied to the estrone affinity column prepared in Example 1. Unbound protein was removed by washing the column with phosphate-buffered saline [0.01M Na 2 HPO 4 - NaH 2 PO 4 /0.15M NaCl (pH7)]. Bound MAB was desorbed with 10mls of an 0.7mg/ml solution of estradiol-glucuronide in phosphate-bufered saline. The recovered MAB was passed down a gel filtration column (G-25 Sephadex, Pharmacia) to remove excess (ie. unbound) estradiol-glucuronide. This procedure would not be expected to remove estradiol-glucuronide that was bound to the MBA.
  • MAB monoclonal antibody
  • a MAB preparation which had been affinity-purified according to the invention (as described in Example 2), had its specific activity compared with that of four MAB batches which had been purified by conventional technology, i.e. on a protein A column Goding (1980) and Hale et al (1994).
  • Each MAB preparations was diluted out to a range of concentrations (as determined by optical density at 280nm - taking an extinction coefficient of 1.4) and then analysed by the protocol described in Example 3.
  • Specific activity (the activity per unit of protein) is given by the steepness of the curves in Figure 2. It is clear that the MAB preparation purified according to the invention (line E in Figure 2) has a higher specific activity than the four preparations purified by conventional technology (lines A to D).
  • the recovered Fv was passed down a gel filtration column (G-25 Sephadex, Pharmacia) to remove excess (i.e. unbound) estriol glucuronide. This procedure would not be expected to remove estriol glucuronide which had bound to the Fv. This experiment was repeated with the same volume of the same Fv-containing feedstock. This time, bound Fv was eluted with a conventional buffer for removing Fv from affinity columns, pH 2 buffer as described in King et al (1993).
  • Example 5 with the assay procedure described in Example 6.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Steroid Compounds (AREA)
  • Detergent Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

On purifie un anticorps spécifique d'un analyte cible par chromatographie d'affinité sur un substrat portant un analogue ayant une faible affinité pour l'analyte cible. L'anticorps se déplace du substrat par contact avec un second analogue possédant une affinité intermédiaire et qui reste complexé à l'anticorps. On peut utiliser ce complexe dans un dosage classique de l'analyte cible, lequel déplace l'analogue possédant l'affinité intermédiaire. On obtient un anticorps complexé plus stable lors de sa conservation, car le second analogue protège la région de fixation de l'anticorps.
PCT/EP1995/004518 1994-11-24 1995-11-16 Recuperation d'agents de liaison specifiques et utilisations de ceux-ci WO1996016332A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU41176/96A AU4117696A (en) 1994-11-24 1995-11-16 Recovery of and uses of specific binding agents
EP95939289A EP0793806B1 (fr) 1994-11-24 1995-11-16 Recuperation d'agents de liaison specifiques et utilisations de ceux-ci
AT95939289T ATE237137T1 (de) 1994-11-24 1995-11-16 Rückgewinnung und verwendungen von spezifischen bindungsreagenzen
DE69530315T DE69530315T2 (de) 1994-11-24 1995-11-16 Rückgewinnung und verwendungen von spezifischen bindungsreagenzen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94308705 1994-11-24
EP94308705.6 1994-11-24

Publications (1)

Publication Number Publication Date
WO1996016332A1 true WO1996016332A1 (fr) 1996-05-30

Family

ID=8217920

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/004518 WO1996016332A1 (fr) 1994-11-24 1995-11-16 Recuperation d'agents de liaison specifiques et utilisations de ceux-ci

Country Status (6)

Country Link
US (1) US5989926A (fr)
EP (1) EP0793806B1 (fr)
AT (1) ATE237137T1 (fr)
AU (1) AU4117696A (fr)
DE (1) DE69530315T2 (fr)
WO (1) WO1996016332A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012270A1 (fr) * 2000-08-03 2002-02-14 Inverness Medical Switzerland Gmbh Peptides capables de fonctionner en tant que mimotopes pour des analytes d'estradiol
WO2015035076A1 (fr) * 2013-09-04 2015-03-12 Sten Ohlson Chromatographie à faible affinité

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4860085B2 (ja) 2000-03-16 2012-01-25 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ 表面結合リガンドから溶出された分析物を捕捉するための方法
US20030119203A1 (en) 2001-12-24 2003-06-26 Kimberly-Clark Worldwide, Inc. Lateral flow assay devices and methods for conducting assays
US7285424B2 (en) 2002-08-27 2007-10-23 Kimberly-Clark Worldwide, Inc. Membrane-based assay devices
US7781172B2 (en) 2003-11-21 2010-08-24 Kimberly-Clark Worldwide, Inc. Method for extending the dynamic detection range of assay devices
US7943395B2 (en) 2003-11-21 2011-05-17 Kimberly-Clark Worldwide, Inc. Extension of the dynamic detection range of assay devices
US7713748B2 (en) 2003-11-21 2010-05-11 Kimberly-Clark Worldwide, Inc. Method of reducing the sensitivity of assay devices
US20050191704A1 (en) * 2004-03-01 2005-09-01 Kimberly-Clark Worldwide, Inc. Assay devices utilizing chemichromic dyes
US7939342B2 (en) 2005-03-30 2011-05-10 Kimberly-Clark Worldwide, Inc. Diagnostic test kits employing an internal calibration system
US7803319B2 (en) 2005-04-29 2010-09-28 Kimberly-Clark Worldwide, Inc. Metering technique for lateral flow assay devices
US7858384B2 (en) 2005-04-29 2010-12-28 Kimberly-Clark Worldwide, Inc. Flow control technique for assay devices
US7439079B2 (en) 2005-04-29 2008-10-21 Kimberly-Clark Worldwide, Inc. Assay devices having detection capabilities within the hook effect region
US8003399B2 (en) * 2005-08-31 2011-08-23 Kimberly-Clark Worldwide, Inc. Nitrite detection technique
US7829347B2 (en) * 2005-08-31 2010-11-09 Kimberly-Clark Worldwide, Inc. Diagnostic test kits with improved detection accuracy
US7504235B2 (en) * 2005-08-31 2009-03-17 Kimberly-Clark Worldwide, Inc. Enzyme detection technique
US7279136B2 (en) 2005-12-13 2007-10-09 Takeuchi James M Metering technique for lateral flow assay devices
US7618810B2 (en) 2005-12-14 2009-11-17 Kimberly-Clark Worldwide, Inc. Metering strip and method for lateral flow assay devices
US20080057528A1 (en) * 2006-08-30 2008-03-06 Kimberly-Clark Worldwide, Inc. Detection of hydrogen peroxide released by enzyme-catalyzed oxidation of an analyte
US8012761B2 (en) 2006-12-14 2011-09-06 Kimberly-Clark Worldwide, Inc. Detection of formaldehyde in urine samples
US7935538B2 (en) 2006-12-15 2011-05-03 Kimberly-Clark Worldwide, Inc. Indicator immobilization on assay devices
US7846383B2 (en) 2006-12-15 2010-12-07 Kimberly-Clark Worldwide, Inc. Lateral flow assay device and absorbent article containing same
US8377379B2 (en) * 2006-12-15 2013-02-19 Kimberly-Clark Worldwide, Inc. Lateral flow assay device
AU2008303540B2 (en) * 2007-09-27 2012-04-26 Novartis Ag Drug monitoring assay

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985001941A1 (fr) * 1983-10-28 1985-05-09 New England Medical Center Hospitals, Inc. Procede de purification et d'isolation de proteines de coagulation sanguine utilisant des anticorps specifiques de conformation
EP0175269A2 (fr) * 1984-09-21 1986-03-26 University Of Iowa Research Foundation Conjugés immunogéniques et leur utilisation dans un essai de dihydropyridine
EP0324540A1 (fr) * 1988-01-08 1989-07-19 AMERSHAM INTERNATIONAL plc Méthode pour déterminer les fractions libres de ligands dans les liquides biologiques
EP0383313A2 (fr) * 1989-02-15 1990-08-22 Mochida Pharmaceutical Co., Ltd. Réactif d'essai immunologique et kit le contenant
WO1991005262A1 (fr) * 1989-10-02 1991-04-18 University Of Michigan Systeme de detection bioanalytique
WO1995000174A1 (fr) * 1993-06-25 1995-01-05 Public Health Laboratory Service Board Stockage d'anticorps

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952569A (en) * 1985-12-02 1990-08-28 E. I. Du Pont De Nemours And Company Estriol derivatives
WO1993003367A1 (fr) * 1991-07-29 1993-02-18 Serex, Inc. Affinites de liaison differentielles et methodes de detection de dissociation basees sur ces affinites
GB9217864D0 (en) * 1992-08-21 1992-10-07 Unilever Plc Monitoring method

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985001941A1 (fr) * 1983-10-28 1985-05-09 New England Medical Center Hospitals, Inc. Procede de purification et d'isolation de proteines de coagulation sanguine utilisant des anticorps specifiques de conformation
EP0175269A2 (fr) * 1984-09-21 1986-03-26 University Of Iowa Research Foundation Conjugés immunogéniques et leur utilisation dans un essai de dihydropyridine
EP0324540A1 (fr) * 1988-01-08 1989-07-19 AMERSHAM INTERNATIONAL plc Méthode pour déterminer les fractions libres de ligands dans les liquides biologiques
EP0383313A2 (fr) * 1989-02-15 1990-08-22 Mochida Pharmaceutical Co., Ltd. Réactif d'essai immunologique et kit le contenant
WO1991005262A1 (fr) * 1989-10-02 1991-04-18 University Of Michigan Systeme de detection bioanalytique
WO1995000174A1 (fr) * 1993-06-25 1995-01-05 Public Health Laboratory Service Board Stockage d'anticorps

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012270A1 (fr) * 2000-08-03 2002-02-14 Inverness Medical Switzerland Gmbh Peptides capables de fonctionner en tant que mimotopes pour des analytes d'estradiol
WO2015035076A1 (fr) * 2013-09-04 2015-03-12 Sten Ohlson Chromatographie à faible affinité
US9448243B2 (en) 2013-09-04 2016-09-20 Sten Ohlson Weak affinity chromatography

Also Published As

Publication number Publication date
AU4117696A (en) 1996-06-17
DE69530315T2 (de) 2004-02-12
ATE237137T1 (de) 2003-04-15
US5989926A (en) 1999-11-23
EP0793806B1 (fr) 2003-04-09
DE69530315D1 (de) 2003-05-15
EP0793806A1 (fr) 1997-09-10

Similar Documents

Publication Publication Date Title
EP0793806B1 (fr) Recuperation d'agents de liaison specifiques et utilisations de ceux-ci
AU596562B2 (en) Polyclonal antibodies, preparation and use
US20240159781A1 (en) Sandwich assay for small molecules
JPH05249112A (ja) 酵素阻害剤を使用する均質系免疫検定法
JPS6171361A (ja) 抗原性物質の免疫化学的定量的測定方法及び試薬
US20060073536A1 (en) Immunoassays for determining vitamin B12, and reagents and kits therefor
US5518882A (en) Immunological methods of component selection and recovery
JP2002098680A (ja) 親イオウ性ゲルを用いてｐｓａとその分子型を検出する方法
US5468651A (en) Method for determining haptens, use of method and components useful in method
AU628298B2 (en) Method for measuring human insulin
US5616503A (en) Determination of haptens
EP0970107B1 (fr) Derives de cyclosporine et leurs utilisations
EP0396570B1 (fr) Procede de determination de quantite, utilisation et composants
AU2004268163B2 (en) Assay methods and materials for distinguishing analytes and analyte analogues
JP3502497B2 (ja) 複合化被検物質誘導体を用いた競合イムノアッセイ
JPS5856696A (ja) カラムを用いる酵素免疫測定法
AU2537688A (en) Solid-phase non-separation enzyme assay
CA2110019C (fr) Immunodetection de la vitamine b12, reactifs et trousses
JP2716103B2 (ja) イムノアッセイにおける誤結果除去方法
JP2000074917A (ja) ジアセチルポリアミンの測定法及びキット
US5212064A (en) Solid phase non-separation enzyme complementation assay
JP3516526B2 (ja) 安定化された酵素標識抗体
JP2007512543A (ja) ホモジニアスな検出方法
Clausen et al. Immunohistochemistry
WO1997044666A1 (fr) Procedes immunologiques de selection et d'extraction de composants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995939289

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995939289

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1995939289

Country of ref document: EP